ODOBGYNDECODED
Emergency Hub / Vascular

⚡ Massive Pulmonary Embolism

IN REVIEWPENDING CLINICAL VERIFICATIONTIME-CRITICAL PROTOCOLFull clinical topic →
1 RECOGNIZE
  • Acute dyspnoea/chest pain, hypoxaemia, tachycardia, syncope or collapse; hypotension/shock identifies a life-threatening presentation.
  • Consider haemorrhage, cardiomyopathy, ACS, sepsis and AFE concurrently; pregnancy does not justify delaying objective diagnosis.
2 CALL FOR HELP
  • Activate senior obstetric, emergency/medical and anaesthetic/critical-care review together; involve PE/cardiothoracic/interventional specialists urgently for shock.
3 IMMEDIATE ACTION
  1. Support airway/oxygenation and circulation; avoid an unmonitored large fluid load in right-ventricular failure. Start ALS immediately if arrest occurs, with manual uterine displacement when indicated.
  2. If VTE is suspected and no strong contraindication exists, give appropriate anticoagulation while arranging expedited objective testing. Stable suspected PE generally uses LMWH; shock, renal dysfunction or likely procedures may favour IV unfractionated heparin.
  3. For life-threatening unstable PE, the expert team decides thrombolysis versus surgical/catheter reperfusion without waiting for a stable-patient work-up. The drug cards below distinguish treatment anticoagulation and the adult alteplase PE regimen.
  4. Check recent birth/surgery, active bleeding and neuraxial procedures before anticoagulant/thrombolytic decisions; in immediately fatal PE, assess risks against the mortality from withholding reperfusion.

Drug doses & preparation

Choose the regimen for the stated indication. Alternatives are not instructions to give every medicine. Check prior doses, contraindications, concentration and the response before repeating.

Enoxaparin — VTE treatmentRCOGchecked
Dose1 mg/kg using booking/early-pregnancy weight
RouteSubcutaneous
FrequencyEvery 12 hours
DurationFor the remainder of pregnancy and at least 6 weeks postpartum; at least 3 months total anticoagulation
PreparationUse a graduated prefilled syringe of the correct mg strength; inject SC, not IM. Do not interchange mg, mL and anti-Xa units
Max doseWeight-based therapeutic dose; renal dysfunction changes the regimen, not an arbitrary fixed maximum
  • Indication: Confirmed or strongly suspected acute VTE in pregnancy unless anticoagulation is contraindicated
  • Renal / hepatic: CrCl <30 mL/min: specialist regimen; consider IV unfractionated heparin when rapid reversal is needed
Monitoring
  • Baseline CBC/platelets, renal/liver function and bleeding risk; clinical response
  • Routine anti-Xa monitoring is not needed for most women; consider extremes of weight, renal impairment or recurrent VTE
  • Stop therapeutic LMWH at least 24 h before planned neuraxial procedures; anaesthetic staff must prescribe postpartum restart using puncture time, catheter removal and haemostasis
Contraindications: Active major bleeding, heparin-induced thrombocytopenia or imminent urgent surgery without an anticoagulation plan
Unfractionated heparin — acute PERCOGchecked
Dose80 units/kg IV loading, then 18 units/kg/hour; subsequent changes follow APTT/anti-Xa nomogram
RouteIV loading + IV infusion
FrequencyContinuous infusion after the initial loading dose
DurationUntil a definitive anticoagulation/reperfusion plan permits transition; duration individualised around bleeding and procedures
PreparationExample: 25,000 units made up to FINAL 50 mL sodium chloride 0.9% =500 units/mL. Pump mL/h = prescribed units/h ÷500. Independently check vial units/mL, patient weight and label
Max doseNo fixed cumulative ceiling; dose to APTT/anti-Xa with the approved nomogram. Omit/review bolus after thrombolysis or when bleeding risk requires
  • Indication: Selected life-threatening PE, severe renal dysfunction or impending procedures when rapid reversibility is valuable
Monitoring
  • Baseline CBC/platelets, coagulation and renal function; check APTT 6 h after starting and after dose changes
  • Bleeding, Hb/platelets, HIT risk and procedure/neuraxial timing
Contraindications: Active major bleeding or HIT; recent surgery/neuraxial procedure requires a documented specialist risk plan
Alteplase — life-threatening PEGenentech / DailyMedchecked
Dose100 mg over 2 hours (adult Activase-labelled PE regimen)
RouteIV infusion
FrequencyOne reperfusion course
Duration2-hour course followed by monitored anticoagulation planning; arrest dosing may follow a different resuscitation protocol
PreparationReconstitute the specific 50/100 mg vial only with the supplied preservative-free sterile water to 1 mg/mL. Gently swirl, do not shake; use a dedicated line. This PE regimen differs from stroke dosing
Max dose100 mg for the cited adult PE regimen; check local product weight limits and do not borrow an arbitrary stroke bolus schedule
  • Indication: Expert-led reperfusion decision for haemodynamically unstable massive PE; pregnancy/postpartum bleeding risks require simultaneous obstetric/critical-care input
Monitoring
  • Bleeding including genital/surgical/neuraxial sites, neurological status, BP, Hb and coagulation
  • Pause/restart heparin according to APTT and the thrombolysis plan; arrange blood products and procedural alternatives
Contraindications: Major active bleeding, intracranial pathology/recent intracranial surgery and recent invasive procedures are major concerns · In immediately fatal PE, the multidisciplinary team weighs contraindications against the risk of death; do not apply this row to stable suspected PE
4 INVESTIGATIONS (never delaying treatment)
  • ECG, chest radiograph and baseline CBC/coagulation/renal function; urgent CTPA/VQ testing according to the diagnostic pathway.
  • Bedside echocardiography may support decisions in an unstable patient when definitive imaging cannot be obtained safely; a normal study does not universally exclude PE.
5 DEFINITIVE MANAGEMENT
  1. Treat confirmed PE with the chosen anticoagulant and reassess perfusion, oxygenation and bleeding. Reperfusion is for the appropriate high-risk presentation, not every suspected PE.
  2. After thrombolysis/procedure, restart or adjust heparin according to coagulation results and the documented reperfusion plan; do not automatically give another heparin loading bolus.
  3. Continue pregnancy VTE therapy through pregnancy and at least 6 weeks postpartum, with at least 3 months total treatment; plan birth and neuraxial timing in advance.
6 ESCALATION
  • Shock, escalating oxygen/pressor need or arrest: ICU/PE rescue team immediately; consider embolectomy/catheter therapy or extracorporeal support where available.
7 POST-EVENT CARE
  • Provide a written anticoagulant, birth/neuraxial, bleeding and postpartum follow-up plan; consider specialist thrombosis review.
  • Discuss recurrence symptoms, adherence and future-pregnancy prophylaxis.

Admission & discharge after the acute event

Care setting: Urgent hospital assessment; outpatient treatment only through a suitable specialist pathway

Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.

When admission or continued hospital care is needed

  • Suspected PE, haemodynamic or respiratory compromise, major bleeding risk, severe pain, extensive thrombosis or unsafe home treatment requires hospital care; unstable PE needs urgent critical-care treatment.

When clinic, day care or home care may be suitable

  • Selected stable DVT/low-risk patients may be managed outside hospital only after specialist assessment, a safe anticoagulation plan and reliable follow-up/support.

Before going home

  • The diagnosis/continuing investigation plan and anticoagulation indication are clear; oxygenation/haemodynamics and bleeding risk support the selected setting.
  • The patient can self-inject or has assistance, has medicine supply, understands missed-dose/bleeding instructions and has a birth/neuraxial plan if still pregnant.

Discharge medicines and treatment changes

  • Use therapeutic anticoagulation for diagnosed VTE, not the lower prophylaxis dose. RCOG treatment continues through pregnancy and for at least 6 weeks postpartum and at least 3 months in total.
  • Reassess renal function, weight, bleeding risk and breastfeeding suitability; record exactly when to hold/restart around planned birth or procedures.
Medicine doses — use only when indicated

Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.

Only the selected therapeutic regimen, adjusted to the individual patient; not routine prophylaxis.

Enoxaparin — VTE treatmentRCOGchecked
Dose1 mg/kg using booking/early-pregnancy weight
RouteSubcutaneous
FrequencyEvery 12 hours
DurationFor the remainder of pregnancy and at least 6 weeks postpartum; at least 3 months total anticoagulation
PreparationUse a graduated prefilled syringe of the correct mg strength; inject SC, not IM. Do not interchange mg, mL and anti-Xa units
Max doseWeight-based therapeutic dose; renal dysfunction changes the regimen, not an arbitrary fixed maximum
  • Indication: Confirmed or strongly suspected acute VTE in pregnancy unless anticoagulation is contraindicated
  • Renal / hepatic: CrCl <30 mL/min: specialist regimen; consider IV unfractionated heparin when rapid reversal is needed
Monitoring
  • Baseline CBC/platelets, renal/liver function and bleeding risk; clinical response
  • Routine anti-Xa monitoring is not needed for most women; consider extremes of weight, renal impairment or recurrent VTE
  • Stop therapeutic LMWH at least 24 h before planned neuraxial procedures; anaesthetic staff must prescribe postpartum restart using puncture time, catheter removal and haemostasis
Contraindications: Active major bleeding, heparin-induced thrombocytopenia or imminent urgent surgery without an anticoagulation plan

Tests, pending results and their reviewer

  • Assign review of any pending imaging, CBC/renal findings and drug monitoring required for the individual patient.

Home care and counselling

  • Teach injection technique, sharps disposal, bleeding precautions, medicine interactions and the contact route for planned labour/procedures.

Follow-up: when and what to review

WhenAction / responsible service
Before discharge
Name the anticoagulation/obstetric reviewer, provide a supply and book the next clinical review.
Before stopping anticoagulation
Confirm the minimum course is complete and reassess continuing thrombosis risk; do not stop simply because leg symptoms improved.

Return urgently

  • Breathlessness, chest pain, haemoptysis, collapse, worsening unilateral leg symptoms or major bleeding requires immediate care.

Open the complete discharge checklist →

Sources for this plan:
RCOGcheckedRCOGchecked

Sources

RCOGcheckedGenentech / DailyMedcheckedResuscitation Council UKcheckedRCOGcheckedNICE · NG194, recommendationscheckedIndia MoHFW / NHM · LaQshya district-hospital SOP, linked editioncheckedWHO · 2022 official recommendation summarycheckedRCOG · Current public recovery informationcheckedNICE · CG50, recommendationschecked